Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Bayer,Alemtuzumab,Chronic lymphocytic leukaemia (CLL) (3rd-line treatment),Alemtuzumab (Mabcampath),Recommended for decline,Community and Hospital,Oncology Agents and Immunosuppressants
